Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aleve ad dispute

This article was originally published in The Tan Sheet

Executive Summary

McNeil's motion to preliminarily enjoin Bayer from airing "Love of the Game" TV spot for naproxen sodium denied by Newark, N.J. federal Judge Katharine Hayden. In a transcript of her Sept. 27 oral ruling, judge says she "cannot agree with McNeil that this commercial contains an unambiguous message that Aleve works better at relieving pain than Tylenol," and J&J division "has not supported its claim of literal falsity." McNeil sued Bayer in August, claiming the Aleve commercial falsely suggests naproxen "relieves more severe pain or relieves pain more effectively" than Tylenol (1"The Tan Sheet" Aug. 12, 2002, p. 4). McNeil says it has not decided whether to continue lawsuit or appeal ruling...

You may also be interested in...



McNeil, Bayer Aleve Ad Dispute Heats Up With Federal Lawsuit

McNeil Consumer & Specialty Pharmaceuticals' has taken its dispute with Bayer Consumer Care over advertising for Aleve to court, after a NAD decision apparently failed to resolve the conflict

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.

Topics

UsernamePublicRestriction

Register

PS094605

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel